about icvs | People | JPEDROSA


Name: Jorge Pedrosa

Office: I3.12

School Phone: +351 253 604 813

Email: jpedrosa@med.uminho.pt




Keywords: Mycobacteria ulcerans tuberculosis host-parasite interactions


Jorge Pedrosa, born in 1964, holds a degree in Biochemistry and a PhD in Biomedical Sciences.

Jorge Pedrosa is a Full Professor at the School of Medicine (EM) - University of Minho (UM), the EM Vice-Dean for research and a Principal Investigator at the Microbiology and Infection Research Domain at the Life and Health Sciences Research Institute (ICVS) - UM.

In the medical course of the EM, Jorge Pedrosa is the Coordinator of the Curricular Area “Biopathology and Introduction to Therapeutics”, which associates the themes of Pathology, Genetics, Immunology, Microbiology and Pharmacology.

J.Pedrosa's Research Interests are in the field of Health Sciences - Immunology. He is a member of the Microbiology and Infection Research Domain and he is particularly interested in the host immune response against infections by highly virulent mycobacteria, namely Mycobacterium ulcerans, the causative agent of the emergent tropical disease Buruli ulcer, and Mycobacterium tuberculosis, the causative agent of tuberculosis. He is using animal models in Biosafety Level 3 laboratories and collaborating with a network of health care institutions in Portugal and in Africa, to both evaluate new strategies aiming at the modulation of the host immune response (e.g. design of new vaccines) and to develop new systems of specific delivery of antimicrobial agents to infected cells.

Jorge Pedrosa has published more than 60 peer-reviewed research articles that have been cited more than 1000 times.

His main Research Contributions include:

·       First demonstration of a protective role played by neutrophils in the early phase ofexperimental tuberculosis.


·    First isolation from the environment of a pure culture of M. ulcerans,the causative agent of the emergent infectious disease Buruli ulcer, implicating the involvement of aquatic insects in the transmission of this neglected disease.


·       Characterization of the host inflammatory response to M. ulcerans;


·      First description of an intracellular growth phase for M. ulcerans, as well as of the mechanisms of macrophage-mediated immune control for this pathogen.



He has received awards and honours for his research accomplishments,including:


- “Pulido Valente Ciência” Award,2010,Fundação Pulido Valente and Fundação para a Ciência e a Tecnologia (FCT)

Best Paper Award, 2010, Portuguese Society for Immunology (SPI)

- Award “Excelência em Imunologia M. Arala-Chaves”, 2006, Portuguese Society for Immunology (SPI)

- Pfizer Award of Research, 1994, Lisboa

- Boa Esperança Science Award, 1989, JNICT, Lisboa


J. Pedrosa has been responsible for several projects funded by national and international agencies and different companies. This includes more than in 11 projects with external funding: in 5 as Coordinator; in 6 as responsible for teams with specific tasks. The most recent projects include:

- lmmunogenetic determinants of susceptibility/resistance to Buruli ulcer: a family- and population-based studyfor a neglected tropical disease. FCT, 2018 - 2021; POCI-01-0145-FEDER-031312

- Transcriptome Analysis of Animal Models of Spontaneous Healing of Buruli Ulcer. Infect-Era, 2016-2019; INFECT-ERA, BU_SPONT_HEAL

- SynPhage: Construction of synthetic phages to combatinfectious bacterial diseases. FCT, 2016-2019; PTDC/BBB-BSS/6471/2014

- Development of a novel colour-coded RING FISHmethod: an innovative tool for the detection of antibiotic resistant clinical pathogens. FCT, 2016-2019; PTDC/DTP-PIC/4562/2014

- BURULIVAC: identification and development of a vaccine against Buruli Ulcer. Seventh Framework Programme. 2010-2014; Grant agreement no.: 241500

15 of his most relevant papers are listed below:


- Fraga AG,Trigo G., Murthy RK, Akhtar S, Hebbur M, Pacheco AR, Dominguez J, Silva-GomesR, Gonçalves CM, Oliveira H, Castro AG, Sharma U, Azeredo J and Pedrosa J. Antimicrobial activity of Mycobacteriophage D29 Lysin B during Mycobacterium ulcerans infection. PLoS Negl Trop Dis. 2019. Accepted for publication


- Capela C,Dossou AD, Silva-Gomes R, Sopoh GE, Makoutode M, Menino JF, Fraga AG, Cunha C,Carvalho A, Rodrigues F, Pedrosa J. Genetic Variation in Autophagy-Related Genes Influences the Risk and Phenotype of Buruli Ulcer. PLoS Negl Trop Dis. 2016 Apr 29;10(4):e0004671. doi: 10.1371/journal.pntd.0004671


- Capela C,Sopoh GE, Houezo JG, Fiodessihoué R, Dossou AD, Costa P, Fraga AG, Menino JF,Silva-Gomes R, Ouendo EM, Rodrigues F, Pedrosa J. Clinical Epidemiology of Buruli Ulcer from Benin (2005-2013): Effect of Time-Delay to Diagnosis on Clinical Forms and Severe Phenotypes. PLoS Negl Trop Dis. 2015 Sep10;9(9):e0004005. doi: 10.1371/journal.pntd.0004005.


- Silva-Gomes R,Marcq E, Trigo G, Gonçalves CM, Longatto-Filho A, Castro AG, Pedrosa J, FragaAG. Spontaneous Healing of Mycobacterium ulcerans Lesions in the Guinea Pig Model. PLoS Negl Trop Dis. 2015 Dec 1;9(12):e0004265. doi:10.1371/journal.pntd.0004265.


- Trigo G,Martins TG, Fraga AG, Longatto-Filho A, Castro AG, Azeredo J, Pedrosa J. Phage therapy is effective against infection by Mycobacterium ulcerans in a murine footpad model. 2013. PLoS Negl Trop Dis. 25;7(4):e2183.


-  Martins TG, Trigo G, Fraga AG, Gama JB,Longatto-Filho A, Saraiva M, Silva MT, Castro AG, Pedrosa J. Corticosteroid-induced immunosuppression ultimately does not compromise the efficacy of antibiotherapy in murine Mycobacterium ulcerans infection. 2012. PLoS Negl Trop Dis. 6(11):e1925.

-  Torrado E, Fraga AG, Logarinho E, Martins TG, Carmona JA, Gama JB, Carvalho MA, Proença F, Castro AG, Pedrosa J. IFN-gamma-dependent activation of macrophages during experimental infections by Mycobacterium ulcerans is impaired by the toxin mycolactone. 2010. J Immunol.184(2):947-55

- Silva MT, PortaelsF,  Pedrosa J. Pathogenetic mechanisms of the intracellular parasite Mycobacterium ulcerans leading to Buruli ulcer. 2009. Lancet Infect. Dis. 9(11):699-710.

- Gaspar MM,Cruz A, Penha AF, Reymão J, Sousa AC, Eleutério CV, Domingues SA, Fraga AG,Filho AL, Cruz ME, Pedrosa J. 2008. Rifabutin encapsulated in liposomes exhibits increased therapeutic activity in a model of disseminated tuberculosis. 2008. Int J Antimicrob Agents. 1:37-45.

- Portaels F,Meyers WM, Ablordey A, Castro AG, Chemlal K, de Rijk P, Elsen P, Fissette K,Fraga AG, Lee R, Mahrous E, Small PL, Stragier P, Torrado E, Van Aerde A, SilvaMT, Pedrosa J. First Cultivation and Characterization of Mycobacterium ulcerans from the Environment. 2008. PLoS Negl Trop Dis 26;2(3):e178.

- Silva MT, Portaels F, Pedrosa J. 2007. Aquatic Insects and Mycobacterium ulcerans: An Association Relevant to Buruli ulcer Control? PLoS Medicine.4(2):e63.

- Torrado E, Adusumilli S, Fraga AG, Small PL, Castro AG, Pedrosa J. Mycolactone-mediated inhibition of TNF production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection. 2007. Infect Immun.75(8): 3979-88.

- Torrado E,Fraga AG, Castro AG, Stragier P, Meyers WM, Portaels F, Silva MT, Pedrosa J. Evidence for an Intramacrophagic Growth Phase of Mycobacterium ulcerans.2007. Infect Immun. 75(2):977-87.

- Cruz A, KhaderSA, Torrado E, Fraga A, Pearl JE, Pedrosa J, Cooper AM, Castro AG. Cuttingedge: IFN-gamma regulates the induction and expansion of IL-17-producing CD4 Tcells during mycobacterial infection. 2006. J Immunol. 1;177(3):1416-20.

- Oliveira MS, Fraga AG, Torrado E, Castro AG, Pereira JP, Filho AL, Milanezi F, Schmitt FC, Meyers WM, Portaels F, Silva MT, Pedrosa J. Infection by Mycobacterium ulcerans induces persistent inflammatory responses in mice. 2005. Infect Immun. 733:6299-6310.



Host pathogen interactions in Mycobacterium ulcerans infection - Buruli Ulcer (Leader) 

Nanomedicine/drug delivery systems to treat mycobacteriosis (Leader) 

Computational Molecular Biology and Evolution of the Mycobacterium tuberculosis Complex  

Evaluation of immune-determinants associated with resistance/susceptibility to Paracoccidioides brasiliensis: a mouse model perspective  

Modulating bacteriostasis in M. tuberculosis infection: impact of the microbiome  

Pathogen Diversity and Epitope-based Immunoinformatics in Tuberculosis  

Understanding BCG vaccination: Correlates of protection/pathology following infection with M. tuberculosis  

Selected Publications

Cruz A, Fraga AG, Fountain JJ, Rangel-Moreno J, Torrado E, Saraiva M, Pereira DR, Randall TD, Pedrosa J, Cooper AM, Castro AG. Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis. J Exp Med. 2010 Aug 2;207(8):1609-16. doi: 10.1084/jem.20100265. Epub 2010 Jul 12.

Silva MT, Portaels F, Pedrosa J. Pathogenetic mechanisms of the intracellular parasite Mycobacterium ulcerans leading to Buruli ulcer. Lancet Infect Dis. 2009 Nov;9(11):699-710. doi: 10.1016/S1473-3099(09)70234-8.

Osório, Nuno S., Fernando Rodrigues, Sebastien Gagneux, Jorge Pedrosa, Marta Pinto-Carbó, António G. Castro, Douglas Young, Iñaki Comas, and Margarida Saraiva. "Evidence for diversifying selection in a set of Mycobacterium tuberculosis genes in response to antibiotic and non-antibiotic related pressure." Molecular Biology and Evolution (2013) 30 (6): 1326-1336. doi: 10.1093/molbev/mst038

Silva JP, Gonçalves C, Costa C, Sousa J, Silva-Gomes R, Castro AG, Pedrosa J, Appelberg R, Gama FM. "Delivery of LLKKK18 loaded into self-assembling hyaluronic acid nanogel for tuberculosis treatment". J Control Release. 2016 Jun 1;235:112-124.

Torrado E, Fraga AG, Logarinho E, Martins TG, Carmona JA, Gama JB, Carvalho MA, Proença F, Castro AG, Pedrosa J. IFN-gamma-dependent activation of macrophages during experimental infections by Mycobacterium ulcerans is impaired by the toxin mycolactone. J Immunol. 2010 Jan 15;184(2):947-55. doi: 10.4049/jimmunol.0902717. Epub 2009 Dec 11.

Copyright © 2012-2016 ICVS. All rights reserved.